What is the Org number of NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI?

NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI is registered with Brønnøysundsregistrene under Org 916307101.

What is the revenue of NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI?

NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI reported revenue of NOK 3,2M in 2024.

Who is the chairman of NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI?

Per Medbøe Thorsby chairs the board of NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI, in role since 2019.

Riskpilot← Back to search

Sign inGet full access

NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI

Q: Who is the CEO of NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI?

Milaim Pepaj is Deputy Member of NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI, in role since 2019.

STIActive

Org 916307101Oslo universitetssykehus HF, Aker, 0424 OsloActivities of other membership organisations n.e.c. · NACE 9499Est. 2015 · 10 years old0 employeeswww.hormonlaboratoriet.no

Overview Financials People & ownership Related companies

Financials

Revenue

NOK millions

EBITDA

NOK millions

Income statement

NOK thousands

Item	2020	2021	2022	2023	2024
Revenue	1 412	1 928	897	2 218	3 178
Staff expenses	−0	−0	−0	−0	−0
EBITDA	−761	1 614	−1 209	1 966	2 743
Depreciation & amort.	−0	−0	−0	−0	−0
EBIT	−761	1 614	−1 209	1 966	2 743
Net financials	0	0	0	0	−1
Profit before tax	−761	1 614	−1 209	1 966	2 743
Tax	−0	−0	−0	−0	−0
Net profit	−761	1 614	−1 209	1 966	2 743

Balance sheet

NOK thousands

Item	2020	2021	2022	2023	2024
Total assets	16 194	17 797	16 558	18 550	21 305
Equity	16 141	17 756	16 547	18 513	21 256
Long-term debt	0	0	0	0	0
Short-term debt	52	41	11	36	49
Total debt	52	41	11	36	49

Financial ratios

5-year trend

EBITDA margin

86.3%

This company

15.8%

Market median

+446% vs market

20202024

Equity ratio

99.8%

This company

38.2%

Market median

+161% vs market

20202024

Return on equity

12.9%

This company

18.4%

Market median

+30% vs market

20202024

Net profit margin

86.3%

This company

8.1%

Market median

+965% vs market

20202024

Asset turnover

0.15×

This company

1.12×

Market median

-87% vs market

20202024

Debt / equity

0.00×

This company

0.62×

Market median

+100% vs market

20202024

Annual reports & filings

Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View PDF

NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI

Financials

Revenue

EBITDA

Income statement

Balance sheet

Financial ratios

Annual reports & filings

More on NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI

Financials

Revenue

EBITDA

Income statement

Balance sheet

Financial ratios

Annual reports & filings

More on NILS NORMANS FORSKNINGSFOND TIL HORMONLABORATORIETS FREMME STI